Skip to main content
. 2022 Oct 25;10(4):e35000. doi: 10.2196/35000

Table 3.

Study characteristics.

Characteristic References Value (N=39), n (%)
Study outcome


Treatment [49,70,71,74,79-81,85,86,90-92,94-98] 17 (44)

Education and training [48,68,69,72,73,75-78,82-84,87-89,93,99-104] 22 (56)
Sample


Students



Medical students [48,68,83,84,87,89,101,102] 8 (21)


Nursing students [72,77,78,104] 4 (10)

Health professionals



Doctors [82,88,93,99,103] 5 (13)


Nurses [73,75] 2 (5)


COVID-19 frontline workers [80,81,100] 3 (8)


Mental health professionals [97,98] 2 (5)

Patient health condition



Recovered in the ICUa due to COVID-19 [49,71,96] 3 (8)


Depression [95] 1 (2)


Chronic back pain [70] 1 (2)


Cerebral palsy [79] 1 (2)


Mild cognitive impairment [91] 1 (2)


Chief complaints of fear of COVID-19 [85] 1 (2)

General population



Healthy individuals [69,74,76,86,90,92,94] 7 (18)
Age range


Under 12 years old N/Ab 0 (0)

12-18 years old [79] 1 (2)

18-35 years old [68,69,72,74,75,78,80,86,87,89,92,94,101,104] 14 (36)

36-55 years old [70,81,85,95,97,98] 6 (15)

Over 55 years old [71,90,91,96] 4 (10)

Unspecified [48,49,73,76,77,82-84,88,93,99,100,102,103] 14 (36)
Gender


Both male and female [68-72,74,75,77-82,85,86,89,91,92,94,97,98,101,102,104,105] 24 (62)

Male only [90,95,96] 3 (8)

Female only N/A 0 (0)

Unspecified [48,49,73,76,83,84,87,88,93,99,100,103] 12 (31)
Nationality


Europe [48,68,69,71,74,81,82,84,86,87,89,90,96-98,102-104] 18 (46)

North America [49,70,72,73,80,83,95,99,101] 9 (23)

South America [79] 1 (2)

Asia [75-78,85,91,92,94] 8 (20)

Africa [93,100] 2 (5)

Oceania N/A 0 (0)

Various [88] 1 (2)
Outcome measures


Self-report questionnaire All 39 (100)

Performance task [68,78,79] 3 (8)

Semistructured interview [95,101,104] 3 (8)

User session data [95,104] 2 (5)

Focus group [104] 1 (2)

Knowledge task [72,73,75-77,100] 6 (15)

Physiological data [73] 1 (2)

aICU: intensive care unit.

bN/A: not applicable.